anti-IL-23R mAbs (CRC-BT/TransBio)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-IL-23R mAbs (CRC-BT/TransBio)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionInterleukin-23 inhibitors

TargetsInterleukin-23

Therapy Area/IndicationsConnective Tissue Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesN/A

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesTransBio Ltd

Active IndicationsN/A

Inactive IndicationsConnective Tissue Diseases

ATC CodeN/A